Publications dans lesquelles il/elle collabore avec RAFAEL DELGADO VÁZQUEZ (17)

2022

  1. Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance

    Open Forum Infectious Diseases, Vol. 9, Núm. 11

2021

  1. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  2. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 3, pp. 738-742

2020

  1. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Analysis of drug resistance mutations in whole blood DNA from HIV-1 infected patients by single genome and ultradeep sequencing analysis

    Journal of Virological Methods, Vol. 260, pp. 1-5

2016

  1. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Different trends of transmitted HIV-1 drug resistance in Madrid, Spain, among risk groups in the last decade

    Archives of Virology, Vol. 159, Núm. 5, pp. 1079-1087

2012

  1. Lack of the detection of XMRV or polytropic MLV-related sequences in blood cells from HIV-1-infected patients in spain

    Journal of Acquired Immune Deficiency Syndromes, Vol. 59, Núm. 2, pp. 101-104

2010

  1. Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy

    Journal of Clinical Microbiology, Vol. 48, Núm. 5, pp. 1911-1912

2009

  1. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258

  2. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis

    Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152

  3. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201

2008

  1. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV

    AIDS, Vol. 22, Núm. 2

2001

  1. GESIDA Consensus document on the use of resistance studies in clinical practice

    Enfermedades infecciosas y microbiología clínica

1996

  1. Alveolar macrophages are not an important source of viral production in HIV-1 infected patients [6]

    AIDS